Last Updated: September 29, 2026

LARIN FE 1.5 Drug Patent Profile

✉ Email this page to a colleague

Which patents cover Larin Fe 1.5, and when can generic versions of Larin Fe 1.5 launch?

Larin Fe 1.5 is a drug marketed by Novast Labs and is included in one NDA.

The generic ingredient in LARIN FE 1.5 is ethinyl estradiol; norethindrone acetate. Twenty-five suppliers are listed for this compound. Additional details are available on the ethinyl estradiol; norethindrone acetate profile page.

AI Deep Research

Questions you can ask:

What is the 5 year forecast for LARIN FE 1.5?
What are the global sales for LARIN FE 1.5?
What is Average Wholesale Price for LARIN FE 1.5?

Summary for LARIN FE 1.5

US Patents:	0
Applicants:	1
NDAs:	1

US Patents and Regulatory Information for LARIN FE 1.5

+ Get email alerts for changes to this table

Glossary

Subscribe to access the full database, or Start Trial
Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Novast Labs	LARIN FE 1.5/30	ethinyl estradiol; norethindrone acetate	TABLET;ORAL-28	091453-001	Aug 23, 2013	AB	RX	No	No	⤷ Start Trial	⤷ Start Trial				⤷ Start Trial
>Applicant	>Tradename	>Generic Name	>Dosage	>NDA	>Approval Date	>TE	>Type	>RLD	>RS	>Patent No.	>Patent Expiration	>Product	>Substance	>Delist Req.	>Exclusivity Expiration

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.